The European Medicines Agency (EMA) contributes to the global response to the novel Coronavirus outbreak, which began in December 2019 in Wuhan, China. Under its plan for managing emerging health threats, EMA is taking concrete actions to accelerate the development and approval of vaccines and medicinal products for the treatment and prevention of the new Coronavirus, together with other regulators in the European Union (EU) and worldwide.
"EMA has activated its plan for managing emerging health threats," says Guido Rasi, the Agency's Executive Director. "The new Coronavirus has been declared a public health emergency of international concern by the World Health Organization, and we are drawing on the strong expertise of the European medicines network to provide fast-track scientific advice and give prompt feedback on any proposed medicine developments”.
There are currently no commercially available medicinal products that are authorised to detect, treat or prevent infections with the novel Coronavirus. EMA is ready to support the medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus.
You can find more detailed information on the novel Coronavirus published by EMA on its website.
The scientific society is making great efforts to deal with this crucial situation and in this framework Fondazione Gianni Benzi will provide further updates in terms of research advancements as more information becomes available.
Keep informed by sharing only verified and reliable information!
In the meantime, follow the tips that Fondazione developed in the framework of its awareness initiative against fake news to learn how to recognise them! #FondazioneBenzivsfakenews